“Off-the-shelf” donor T cells primed to fight five specific viruses were shown to be effective in a Phase 2 trial backed by Viracyte.
A single infusion produced a complete or partial response rate of 92%.
Unfortunately, they did not provide data on the difference between patients and controls in the viral load.
Prevalence of HHV-6A and HHV-6B was evenly divided in HIV patients in Western Africa, with over 6.3% positive for HHV-6 A and 5.0% for HHV-6B.
HHV-6A was more common among those with a low viral HIV viral load.